Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

bioAffinity Technologies (BIAF) Shares Outstanding (2021 - 2026)

bioAffinity Technologies has reported Shares Outstanding over the past 6 years, most recently at $4.5 million for Q1 2026.

  • Quarterly Shares Outstanding rose 657.23% to $4.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Mar 2026, up 657.23% year-over-year, with the annual reading at $4.5 million for FY2025, 786.4% up from the prior year.
  • Shares Outstanding was $4.5 million for Q1 2026 at bioAffinity Technologies, roughly flat from $4.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $11.2 million in Q1 2024 and troughed at $313153.0 in Q4 2023.
  • The 5-year median for Shares Outstanding is $3.5 million (2025), against an average of $4.3 million.
  • Year-over-year, Shares Outstanding surged 1007.82% in 2022 and then tumbled 96.26% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $8.4 million in 2022, then tumbled by 96.26% to $313153.0 in 2023, then soared by 62.07% to $507520.0 in 2024, then soared by 786.4% to $4.5 million in 2025, then changed by 0.0% to $4.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Shares Outstanding are $4.5 million (Q1 2026), $4.5 million (Q4 2025), and $3.5 million (Q3 2025).